Chardan Capital Upgrades Palvella Therapeutics (NASDAQ:PVLA) to “Strong-Buy”

Palvella Therapeutics (NASDAQ:PVLA) was upgraded by investment analysts at Chardan Capital to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other brokerages have also recently issued reports on PVLA. HC Wainwright reaffirmed a “buy” rating and set a $270.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, July 22nd. Stephens restated an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $199.53.

Palvella Therapeutics Stock Up 5.3%

Shares of Palvella Therapeutics stock opened at $150.19 on Tuesday. Palvella Therapeutics has a fifty-two week low of $34.57 and a fifty-two week high of $161.38. The business has a fifty day simple moving average of $129.69 and a 200-day simple moving average of $118.14. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -36.02 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Analysts anticipate that Palvella Therapeutics will post -5.26 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. The trade was a 66.64% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PVLA. First Light Asset Management LLC raised its holdings in Palvella Therapeutics by 38.3% during the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after buying an additional 271,617 shares in the last quarter. Suvretta Capital Management LLC grew its stake in Palvella Therapeutics by 8.5% in the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after buying an additional 70,000 shares during the last quarter. Jennison Associates LLC raised its holdings in Palvella Therapeutics by 65.3% in the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock worth $79,852,000 after acquiring an additional 253,128 shares during the period. Vanguard Group Inc. boosted its holdings in Palvella Therapeutics by 13.3% during the fourth quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after acquiring an additional 65,960 shares during the period. Finally, State Street Corp lifted its position in shares of Palvella Therapeutics by 206.3% during the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after purchasing an additional 283,211 shares during the last quarter. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.